Vitiligo
Conditions
Interventions
experimental group:intramuscular lienal polypeptide solution
vehicle control group:intramuscular lienal polypeptide solution matrix
Sponsors
Beijing Friendship Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Meet the Western medical diagnostic criteria for progressive non-segmental vitiligo; 2. Age >=18 years old, and <=65 years old, gender is not limited; 3. White patches area <=50%; 4. Patients who are receiving conventional clinical treatment (treatment includes topical corticosteroids, calcineurin phosphatase; oral glycyrrhizin, etc.); 5. Voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Depigmentation, anemia, albinism, and white patches caused by other syndromes, senile leukoplakia, apigmented nevus, solar leukoplakia, etc.; 2. Patients with severe primary diseases and mental illnesses of the heart, liver, kidney, hematopoietic and metabolic systems, as well as patients with tuberculosis and tumors; 3. Oral steroid drugs, immunomodulatory drugs, and black light therapy in the past 2 weeks; and/or tretinoin within 1 week; 4. Women who are planning for pregnant, pregnant, or breastfeeding; 5. Suspected or confirmed history of alcohol and drug abuse; 6. Allergies (allergies to more than 2 kinds of food or drugs), or allergies to the drug ingredients of this planning drug; 7. According to the judgment of the investigator, those who have other pathologies that reduce the possibility of enrollment or complicate enrollment, such as frequent changes in working environment, mental disorders, communication difficulties, etc., which the investigator considers unsuitable to participate in this clinical trial; 8. Those who have participated in other drug clinical studies or are participating in other clinical trials in the past 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vitiligo Area ; | — |
Secondary
| Measure | Time frame |
|---|---|
| decreased value of Vitiligo Area and Severity Index;response rate of VASI 35;response rate of VASI 90; | — |
Countries
China
Contacts
Public ContactLi Linfeng
Beijing Friendship Hospital, Capital Medical University
Outcome results
None listed